Drug Profile
Motolimod-Array Pharma/Celgene
Alternative Names: VTX-2337Latest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Celgene Corporation
- Class Amides; Antineoplastics; Benzazepines; Pyrrolidines; Small molecules
- Mechanism of Action Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer
- No development reported Breast cancer; Lymphoma
- Discontinued B-cell lymphoma
Most Recent Events
- 23 Feb 2023 Celgene terminates phase-I trial in Squamous cell cancer (Combination therapy) in USA (SC) due to business objective changes (NCT03906526)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Squamous-cell-cancer(Combination therapy) in USA (Intratumoural, Injection)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Squamous-cell-cancer(Combination therapy) in USA (SC, Injection)